Fosamax and Osteonecrosis of the Jaw: A Clinical Evidence Review of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Bone Health to Specific Pharmaceutical Risks

The legacy context of general health and science information has long provided a foundational framework for understanding broad physiological principles and disease prevention. Within this heritage, public health communications have historically emphasized the importance of bone health, often through dietary guidance and awareness of conditions such as osteoporosis. This general health perspective serves as a necessary backdrop for more specialized inquiries into the effects of specific pharmaceutical interventions on skeletal integrity. Transitioning from this broad foundation, attention now turns to a more focused area of clinical concern: the relationship between bisphosphonate therapy, particularly Fosamax, and the risk of osteonecrosis of the jaw. This pivot moves from general health maintenance to a specific exposure scenario in which patients receiving long-term treatment for bone density loss may face an elevated risk of adverse oral outcomes. The clinical evidence review of Fosamax and osteonecrosis of the jaw causation represents a shift from population-level health education to individual-level risk assessment, where the therapeutic benefits of the drug must be weighed against potential complications. This transition underscores the need for careful monitoring and informed clinical decision-making when managing patients on bisphosphonate regimens.

Clinical Presentation and Diagnosis of Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is defined as exposed necrotic bone in the maxillofacial region that persists for more than eight weeks in the absence of prior radiation therapy. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation includes pain, swelling, purulent discharge, and exposed bone in the oral cavity. Diagnosis is primarily clinical, supported by imaging such as panoramic radiography or computed tomography. The condition is distinct from other jaw pathologies due to its association with bisphosphonate use and lack of metastatic disease. Multiscale characterization of jawbone tissue has provided comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research underscores the unique vulnerability of the jawbone to bisphosphonate-induced injury.

Fosamax Pharmacology and Reported Adverse Effects

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but a serious adverse effect—osteonecrosis of the jaw (ONJ)—has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Fosamax is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. The drug's long half-life in bone leads to prolonged suppression of bone remodeling. Adverse effects include gastrointestinal symptoms, musculoskeletal pain, and, notably, osteonecrosis of the jaw. In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, postmarketing surveillance has identified ONJ as a rare but serious adverse event. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping, but a subset experienced recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Pathways Linking Fosamax to Osteonecrosis of the Jaw

The pathogenesis of bisphosphonate-related ONJ involves multiple mechanisms. Bisphosphonates like Fosamax suppress osteoclast activity, reducing bone turnover and impairing the repair of microdamage. In the jawbone, which undergoes high remodeling due to masticatory forces and dental infections, this suppression can lead to necrosis. Additionally, bisphosphonates may inhibit angiogenesis, reduce immune function, and exert direct toxic effects on oral epithelium. The multiscale characterization of jawbone tissue has revealed that the jawbone's unique structure and cellular composition may predispose it to bisphosphonate-related complications (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings help explain why ONJ occurs predominantly in the jaw rather than other skeletal sites.

Risk Factors and Adequacy of Warnings

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The prescribing information for Fosamax includes a warning about ONJ, stating that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the adequacy of these warnings has been questioned, as the condition may occur without recognized risk factors and the label does not specify the magnitude of risk or provide detailed guidance on dental management for all patients.

Causation-Related Considerations for Affected Patients

Establishing causation between Fosamax and ONJ requires careful assessment of temporal relationship, exclusion of other causes, and biological plausibility. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In some cases, ONJ developed after years of bisphosphonate therapy. The recurrence of symptoms upon rechallenge with the same drug or another bisphosphonate supports a causal role (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For affected patients, key considerations include the duration and dose of Fosamax exposure, presence of other risk factors, and the timing of dental procedures. The label recommends discontinuation of bisphosphonate treatment for patients requiring invasive dental procedures to reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of drug holiday and the management of established ONJ remain areas of clinical uncertainty.

Timeline Between Exposure and Documented Harm

The timeline between Fosamax exposure and ONJ onset is variable. Symptoms may appear as early as one day after starting the drug or after several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief after discontinuation, but a subset has recurrence upon rechallenge (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This temporal variability complicates risk assessment and underscores the need for ongoing monitoring in patients on long-term therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ)?

Osteonecrosis of the jaw is a condition characterized by exposed necrotic bone in the maxillofacial region that persists for more than eight weeks in the absence of prior radiation therapy. It is associated with bisphosphonate use, including Fosamax, and often presents with pain, swelling, and exposed bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How does Fosamax cause osteonecrosis of the jaw?

Fosamax suppresses osteoclast activity, reducing bone turnover and impairing repair of microdamage. In the jawbone, which undergoes high remodeling, this suppression can lead to necrosis. Additional mechanisms include inhibition of angiogenesis and direct toxic effects on oral epithelium (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, periodontal disease, and longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long after starting Fosamax can ONJ occur?

Symptoms may appear as early as one day after starting the drug or after several months. The risk may increase with longer duration of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.